| 罗自娟 曹晨 孙娟娟 张华章 王静.多西紫杉醇与紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌的疗效比较[J].,2016,16(10):1934-1936 |
| 多西紫杉醇与紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌的疗效比较 |
| Advanced Cervical Cancer: Efficacy Comparison of Docetaxel and Paclitaxelcombined with Cisplatin Chemotherapy and Radiotherapy |
| |
| DOI： |
| 中文关键词: 宫颈癌 同步放化疗 紫杉醇 多西紫杉醇 顺铂 |
| 英文关键词: Cervical cancer Synchronous radiotherapy and chemotherapy Paclitaxel Docetaxel Cisplatin |
| 基金项目: |
|
| 摘要点击次数: 843 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：比较多西紫杉醇与紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌的疗效。方法：选择2006 年6 月至2012 年6月我院收
治的宫颈癌晚期患者180 例作为研究对象，依据随机数字表将患者分为紫杉醇组（n=90）和多西紫杉醇组（n=90），两组患者在放
疗基础上分别接受紫杉醇135 mg/m2，每周1 次，多西紫杉醇25 mg/m2，每周1 次，4 周一疗程，维持两个疗程，比较两组患者的近
期疗效、生存时间和毒副作用发生情况。结果：紫杉醇和多西紫杉醇组近期治疗的总有效率分别为81.11%和87.78%，差异无统计
学意义（P=0.217）；且均未出现进展期的病例。紫杉醇组3 年生存率为58.89%，明显低于多西紫杉醇组的75.56%，差异有统计学
意义（P=0.017）；紫杉醇组骨髓抑制和消化道反应的发生率分别为35.56%和37.78%，明显高于多西紫杉醇组的22.22%和
26.67%，差异有统计学意义（均P<0.05）。结论：多西紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌能显著提高患者3 年生存率，降
低毒副作用发生率，且用药量更少，相对安全、合理，患者可耐受，值得进一步临床研究。 |
| 英文摘要: |
| Objective:To compare the efficacy of docetaxel and paclitaxel combined with cisplatin chemotherapy and
radiotherapy in the treatment of patients with advanced cervical cancer.Methods:A total of 180 patients with advanced cervical cancer,
who were treated in Wuhan Commercial Staff and Workers Hospital from June 2006 to June 2012, were chosen as the research subjects
and randomly divided into paclitaxel group(n=90) and docetaxel group(n=90). On the basis of radiotherapy, the two groups were treated
with paclitaxel 135 mg/m2 once a week, docetaxel 25 mg/m2 once a week respectively, 4 weeks as a course of treatment, maintaining two
courses. Then the short-term efficacy, survival time and side effects in the two groups were compared.Results:Total efficiency of
short-term efficacy in paclitaxel group and docetaxel group were 81.11% and 87.78% respectively, the difference had no statistical
significance (P=0.217), and there was no progressive patients. The survival rate (58.89%) of 3 years in paclitaxel group was significantly
lower than that (75.56%) in docetaxel group, the difference was statistically significant (P=0.017). The incidence of bone marrow
suppression (35.56%) and gastrointestinal reaction (37.78%) in the paclitaxel group were significantly higher than those (22.22% and
26.67%) in the docetaxel group, the differences were statistically significant (P<0.05).Conclusion:Docetaxel combined with cisplatin
chemotherapy and radiotherapy can significantly improve 3-year-survival rate and reduce the incidence of side effects in the treatment of
patients with advanced cervical cancer, with lower chemotherapy dosage, safety and tolerability for the patients, which is worthy of
further clinical study. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
